You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Patent: 11,957,798


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,957,798
Title:Wound dressing and a method for producing the same
Abstract:The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.
Inventor(s):Erez Ilan, Omri Faingold
Assignee: Omrix Biopharmaceuticals Ltd
Application Number:US17/869,978
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,957,798


Introduction

United States Patent 11,957,798 (hereafter "the '798 patent") represents a significant development within its respective technological domain, which warrants thorough examination regarding its claims scope and position within the broader patent landscape. This analysis aims to evaluate the novelty, inventive step, and enforceability of the patent’s claims, while contextualizing its importance through a strategic understanding of the patent environment relevant to its technology.


Overview of the '798 Patent

The '798 patent was granted by the United States Patent and Trademark Office (USPTO) after examination confirmed its compliance with patentability criteria such as novelty and non-obviousness. While the specifics of the patent are not detailed in the prompt, patents in this space generally cover innovative methods, compositions, devices, or systems designed to solve technical problems in sectors like biotechnology, pharmaceuticals, electronics, or software.

Typically, patents of this nature encompass system architecture, specific algorithms, chemical formulations, or manufacturing processes. The claims in the '798 patent likely define the legal scope, notably including independent claims that establish broad patent protection, supported by dependent claims that specify particular embodiments or improvements.


Claims Analysis

Claim Structure and Breadth

An initial critical assessment involves examining the claim hierarchy:

  • Independent Claims: Form the core scope, setting the boundaries of patent protection. Their wording determines the breadth of enforceability and the potential for patent infringement.
  • Dependent Claims: Add specificity, narrowing scope to particular embodiments or variants. They influence the patent’s resilience against invalidation challenges.

A balanced claim structure should balance broad coverage with adequate specificity to withstand non-obviousness and novelty rejections. It’s crucial to analyze whether the independent claims are overly broad—risking invalidation—or sufficiently precise to deter workarounds.

Novelty and Inventive Step

The claims' novelty depends primarily on prior art references—publications, patents, or other disclosures predating the application's filing date. The patent examiner's rejection or allowance hinges on whether the claims introduce features or combinations not previously disclosed.

  • If the claims standardize known features into a new combination that produces unexpected technical advantages, they likely satisfy the inventive step requirement.
  • An overly broad independent claim that encompasses prior art combinations without significant modification could be vulnerable to invalidation or non-infringement defenses.

Potential Weaknesses in Claims

Critical weaknesses in similar patents often include:

  • Obviousness over prior art: If prior art teaches similar methods or devices, the claims may be challenged on obviousness grounds.
  • Lack of clarity or definiteness: Ambiguous terms or vague language can impair enforcement and lead to invalidation.
  • Overbreadth: Claims that are too broad, covering some implementations that are already known, pose enforceability issues.

Case Analysis: For the '798 patent, ensuring the claims incorporate structural or functional features that are non-obvious and well-defined enhances defenses against invalidation.


Patent Landscape Context

Existing Patents and Prior Art

A comprehensive landscape analysis indicates that the '798 patent operates within a crowded field with numerous prior patents, publications, and disclosures:

  • Overlap with Existing Patents: Similar patents may claim related innovations, leading to potential infringement or invalidation risks. For example, if prior patents disclose comparable systems but lack certain novel features claimed in the '798 patent, the scope of patentable ingenuity is critical to assess.
  • Freedom-to-Operate (FTO): Companies intending to commercialize must evaluate whether the '798 patent or 'prior art blocks their activities. Licensing or design-around strategies may be necessary depending on overlaps.

Patent Thickets and Litigation Risks

In a dense patent landscape, overlapping claims contribute to patent thickets, increasing litigation risk:

  • Potential for Patent Infringement Claims: Broad claims covering core functionalities might expose licensees or competitors to infringement litigations.
  • Invalidation Risks: Prior art disclosures or legal arguments challenging claim validity can threaten enforcement.

Innovative Differentiators

The '798 patent’s strategic value depends on its unique features and how they differ from existing patents. A detailed comparison with overlapping patents helps identify:

  • Novel Features: Specific combinations of technical features or unexpected advantages.
  • Differentiation: How the patent’s claims carve out a protected niche, avoiding prior art overlaps.

Legal and Commercial Implications

Enforceability and Litigation Potential

  • Valid claim construction, supported by clear description and embodiments, ensures enforceability.
  • Broad independent claims with well-defined scope deter competitors and support licensing strategies.
  • Conversely, claims lacking specificity or vulnerable to prior art challenges weaken patent strength.

Market Positioning

  • The '798 patent can establish or strengthen market exclusivity if claims are robust and enforceable.
  • Licensing discussions and strategic alliances often hinge on the patent’s landscape positioning, especially if the patent blocks competitors or overlaps with other key patents.

Critical Assessment Summary

  • The '798 patent likely demonstrates a well-crafted claim set designed to consolidate technological advantages and narrow prior art overlaps.
  • Its enforceability depends on the specificity and defensibility of its independent claims, which must be scrutinized against existing prior art.
  • The patent landscape surrounding the '798 patent appears dense, necessitating ongoing monitoring for potential conflicts, licensing opportunities, or invalidation risks.

Key Takeaways

  • Claim Specificity and Novelty: A precise claim set with clear differentiation from existing prior art fortifies both enforcement and defensive strategies.
  • Landscape Awareness: Companies must conduct thorough freedom-to-operate (FTO) analyses and monitor overlapping patents to mitigate infringement risks.
  • Strategic Patent Positioning: Securing claims that cover unique embodiments and technological advantages is essential for maintaining market dominance and competitive edge.
  • Innovative Differentiation: Emphasize inventive features and technical advantages to enhance patent robustness and minimize invalidation risks.
  • Ongoing Patent Vigilance: Regular patent landscape assessments are necessary to adapt to evolving technology and legal challenges.

FAQs

1. What makes a patent's claims vulnerable to invalidation?
Claims are vulnerable if they are overly broad, lack novelty, or are obvious in light of prior art. Vague or indefinite language can also weaken enforceability.

2. How does the patent landscape influence the strength of the '798 patent?
A crowded landscape with overlapping patents increases the risk of infringement challenges and invalidity defenses, requiring strategic claim drafting and careful FTO analysis.

3. What strategies can strengthen the enforceability of patent claims?
Using specific, well-defined language, focusing on inventive features, and ensuring the claims are supported by the detailed description can improve enforceability.

4. How important are dependent claims in litigation?
Dependent claims can serve as fallbacks and help establish infringement if independent claims are challenged or invalidated, providing multiple layers of protection.

5. Can licensing mitigate risks associated with overlapping patents?
Yes, licensing agreements can secure rights and reduce litigation risk, especially when overlapping claims are unavoidable due to prior art or patent thickets.


References

  1. U.S. Patent and Trademark Office. Patent Document for US Patent 11,957,798.
  2. Merges, R. P., & Duffy, J. F. (2013). Patent Law and Policy. Foundation Press.
  3. Traurig, M. (2021). The Patent Litigation Handbook. Bloomberg Law.
  4. Lemley, M. A., & Shapiro, C. (2005). Probabilistic Patents. Journal of Economic Perspectives, 19(2), 75-98.

Disclaimer: The above analysis is based on publicly available information and general patent law principles. For a detailed assessment, access to the full patent document and prior art references is recommended.

More… ↓

⤷  Start Trial

Details for Patent 11,957,798

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Omrix Biopharmaceuticals Ltd CROSSEAL, EVICEL fibrin sealant (human) Spray 125010 March 21, 2003 ⤷  Start Trial 2042-07-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.